BACKGROUND: About 5% of all breast cancer cases are attributable to germline mutations in BRCA1 or BRCA2 genes. BRCA mutations in suspected carriers, however, may be missed, which hampers genetic counselling. MATERIALS AND METHODS: Different clinicopathological features were compared between 22 breast cancers from carriers of proved BRCA1 mutations and 604 cancers from sporadic controls. In addition, 5 BRCA2-related breast cancers and 66 breast cancers of untested patients at intermediate risk and 19 breast cancers of untested patients at high risk of hereditary disease on the basis of family history were evaluated. RESULTS: A "probably sporadic" class (age >or=54 years and epidermal growth factor receptor (EGFR) negative; 68% of cases) with a 0% chance of BRCA1-related breast cancer containing 79% of the sporadic cases was yielded by using a decision tree with age, Ki67 and EGFR. A 75% chance of BRCA1-related breast cancer was shown by the "probably BRCA1-related" class (age <54 years and Ki67 >or=25%; 8% of cases) with 82% of the BRCA1-related cases but only 1.4% of the sporadic cases. Most cases at intermediate or high risk of hereditary disease on the basis of family history could be classified with high probability as either probably BRCA1 related or probably sporadic. CONCLUSION: Breast carcinomas can be classified with a high level of certainty as sporadic or related to BRCA1 germline mutations by using a decision tree with age, Ki67 and EGFR. This can be clinically useful in mutation analysis in families with a borderline risk of hereditary disease.
BACKGROUND: About 5% of all breast cancer cases are attributable to germline mutations in BRCA1 or BRCA2 genes. BRCA mutations in suspected carriers, however, may be missed, which hampers genetic counselling. MATERIALS AND METHODS: Different clinicopathological features were compared between 22 breast cancers from carriers of proved BRCA1 mutations and 604 cancers from sporadic controls. In addition, 5 BRCA2-related breast cancers and 66 breast cancers of untested patients at intermediate risk and 19 breast cancers of untested patients at high risk of hereditary disease on the basis of family history were evaluated. RESULTS: A "probably sporadic" class (age >or=54 years and epidermal growth factor receptor (EGFR) negative; 68% of cases) with a 0% chance of BRCA1-related breast cancer containing 79% of the sporadic cases was yielded by using a decision tree with age, Ki67 and EGFR. A 75% chance of BRCA1-related breast cancer was shown by the "probably BRCA1-related" class (age <54 years and Ki67 >or=25%; 8% of cases) with 82% of the BRCA1-related cases but only 1.4% of the sporadic cases. Most cases at intermediate or high risk of hereditary disease on the basis of family history could be classified with high probability as either probably BRCA1 related or probably sporadic. CONCLUSION:Breast carcinomas can be classified with a high level of certainty as sporadic or related to BRCA1 germline mutations by using a decision tree with age, Ki67 and EGFR. This can be clinically useful in mutation analysis in families with a borderline risk of hereditary disease.
Authors: Petra van der Groep; Alwin Bouter; Richard van der Zanden; Fred H Menko; Horst Buerger; Rene H M Verheijen; Elsken van der Wall; Paul J van Diest Journal: J Natl Cancer Inst Date: 2004-05-05 Impact factor: 13.506
Authors: M Robson; P Rajan; P P Rosen; T Gilewski; Y Hirschaut; P Pressman; B Haas; L Norton; K Offit Journal: Cancer Res Date: 1998-05-01 Impact factor: 12.701
Authors: P J van Diest; J P Baak; P Matze-Cok; E C Wisse-Brekelmans; C M van Galen; P H Kurver; S M Bellot; J Fijnheer; L H van Gorp; W S Kwee Journal: Hum Pathol Date: 1992-06 Impact factor: 3.466
Authors: R P Zweemer; R H Verheijen; F H Menko; J J Gille; P J van Diest; J W Coebergh; P A Shaw; I J Jacobs; P Kenemans Journal: Eur J Obstet Gynecol Reprod Biol Date: 1999-02 Impact factor: 2.435
Authors: William D Foulkes; Jean-Sébastien Brunet; Ingunn M Stefansson; Oddbjørn Straume; Pierre O Chappuis; Louis R Bégin; Nancy Hamel; John R Goffin; Nora Wong; Michel Trudel; Linda Kapusta; Peggy Porter; Lars A Akslen Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Bar Chikman; Tima Davidson; Hasan Kais; Igor Jeroukhimov; Ari Leshno; Judith Sandbank; Ariel Halevy; Ron Lavy Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West Journal: Hugo J Date: 2010-04-10
Authors: Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem Journal: Int J Clin Exp Pathol Date: 2013-12-15
Authors: Ashish Juvekar; Laura N Burga; Hai Hu; Elaine P Lunsford; Yasir H Ibrahim; Judith Balmañà; Anbazhagan Rajendran; Antonella Papa; Katherine Spencer; Costas A Lyssiotis; Caterina Nardella; Pier Paolo Pandolfi; José Baselga; Ralph Scully; John M Asara; Lewis C Cantley; Gerburg M Wulf Journal: Cancer Discov Date: 2012-08-22 Impact factor: 39.397
Authors: Laura N Burga; Nadine M Tung; Susan L Troyan; Mihnea Bostina; Panagiotis A Konstantinopoulos; Helena Fountzilas; Dimitrios Spentzos; Alexander Miron; Yosuf A Yassin; Bernard T Lee; Gerburg M Wulf Journal: Cancer Res Date: 2009-02-03 Impact factor: 12.701